CUE SEC Filings: 8-K, 10-Q, S-3 & 424B – Cue Biopharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cue Biopharma Announces Positive Topline Phase 2 Results for CUE-221 in Chronic Spontaneous Urticaria

Sep 21, 2026

8-K

Cue Biopharma, Inc. Announces Financial Results for the Quarter Ended June 30, 2026

Aug 14, 2026

8-K

Cue Biopharma Appoints James Ahlers as Chief Financial Officer

Aug 3, 2026

8-K

Cue Biopharma Announces $50.0 Million Private Placement

Jul 10, 2026

8-K

Cue Biopharma, Inc. Announces Results of Special Meeting of Stockholders

Jun 3, 2026

8-K

Cue Biopharma Announces Board Resignations, New Appointments, and Executive Leadership Changes

Jun 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Dec 19, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: H.C. Wainwright & Co.

Dec 18, 2025

424B5

REGISTERED OFFERING

Apr 15, 2025

424B5

SHELF OFFERING | Bank: Oppenheimer & Co.

Apr 14, 2025

424B5

Sep 27, 2024

424B5

PENDING OFFERING | Bank: Oppenheimer & Co.

Sep 26, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Aug 12, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jul 22, 2026

S-3

SHARE RESALE REGISTRATION

Jun 18, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 3, 2026

S-3

SHARE RESALE REGISTRATION

Jun 3, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

May 14, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 21, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

May 12, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 16, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 6, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 27, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Ray Sumita (Reporting)

Oct 14, 2026

Meluzio Michael Vincent (Reporting)

Oct 14, 2026

Lin Shao-Lee (Reporting)

Oct 14, 2026

144

Form 144 - Report of proposed sale of securities

Oct 13, 2026

144

Form 144 - Report of proposed sale of securities

Oct 13, 2026

SCHEDULE 13G/A

STROME MARK E (Filed by)

Oct 8, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 21, 2026

CORRESP

Form CORRESP - Correspondence

Aug 18, 2026

LETTER

Form UPLOAD - SEC-generated letter

Aug 17, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 2, 2026

CORRESP

Form CORRESP - Correspondence

Jun 29, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 25, 2026

Cue Biopharma, Inc. CUE · SEC Filings